Search

Roche Holding AG

Deschisă

SectorSănătate

355.6 2.01

Rezumat

Modificarea prețului

24h

Curent

Minim

344

Maxim

355

Indicatori cheie

By Trading Economics

Venit

3.7B

Vânzări

16B

P/E

Medie Sector

30.929

90.422

Randament dividend

2.72

Marjă de profit

23.266

Angajați

103,249

EBITDA

6.5B

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.72%

2.13%

Statistici piață

By TradingEconomics

Capitalizare de piață

289B

Deschiderea anterioară

353.59

Închiderea anterioară

355.6

Sentimentul știrilor

By Acuity

21%

79%

37 / 352 Clasament în Healthcare

Roche Holding AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 ian. 2026, 10:07 UTC

Câștiguri

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 ian. 2026, 07:07 UTC

Câștiguri

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18 nov. 2025, 11:04 UTC

Principalele dinamici ale pieței

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23 oct. 2025, 09:32 UTC

Câștiguri

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 oct. 2025, 05:54 UTC

Câștiguri

Roche Raises Full-Year Earnings Outlook

29 ian. 2026, 11:40 UTC

Market Talk
Câștiguri

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 ian. 2026, 06:05 UTC

Câștiguri

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 ian. 2026, 06:04 UTC

Câștiguri

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 ian. 2026, 06:03 UTC

Câștiguri

Roche Issues 2026 View

29 ian. 2026, 06:02 UTC

Câștiguri

Analysts Saw 2025 Core EPS at CHF19.70

29 ian. 2026, 06:02 UTC

Câștiguri

Roche: 2025 Core EPS CHF19.46

29 ian. 2026, 06:01 UTC

Câștiguri

Analysts Had Seen 2025 Sales At CHF61.47B

29 ian. 2026, 06:01 UTC

Câștiguri

Roche 2025 Sales CHF61.52B

28 ian. 2026, 11:22 UTC

Câștiguri

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 ian. 2026, 11:31 UTC

Market Talk

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 ian. 2026, 11:24 UTC

Market Talk

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 ian. 2026, 09:30 UTC

Market Talk

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 ian. 2026, 07:52 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Roche Obesity Study Data Look Encouraging -- Market Talk

16 ian. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 ian. 2026, 14:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Pharma Sector Can Spend Big on M&A -- Market Talk

22 dec. 2025, 08:48 UTC

Market Talk

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 nov. 2025, 12:47 UTC

Market Talk

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10 nov. 2025, 12:16 UTC

Market Talk
Câștiguri

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23 oct. 2025, 09:19 UTC

Market Talk
Câștiguri

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 oct. 2025, 09:11 UTC

Market Talk
Câștiguri

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 oct. 2025, 05:09 UTC

Câștiguri

Roche 3Q Sales Up 6% At CER

23 oct. 2025, 05:07 UTC

Câștiguri

Roche 3Q Sales CHF14.92B

23 oct. 2025, 05:07 UTC

Câștiguri

Analysts Had Seen 3Q Sales At CHF15.17B

23 oct. 2025, 05:07 UTC

Câștiguri

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 oct. 2025, 05:05 UTC

Câștiguri

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

Roche Holding AG Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

37 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat